Filer Snapshot

Paradigm Biocapital Advisors LP

CIK 0001855655. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

49

Latest filing

15 May 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Largest parsed holding

ACLX

$662.97M reported value

Open holding

13D/G large stake

ASMB

04 May 2026 · 5.4% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13G/A filed on 15 May 2026 for CIK 0001855655.

View Source Filing
SEC ownership signals 1 fact
SEC ownership summary

Filing-value scale

Bars compare parsed values by filing family; they are not one combined total.

Latest 13F portfolio$4.89B

Quarterly institutional portfolio holdings.

Forms 3/4/5 positions$173.77M

Reporting-owner positions when a value can be estimated.

Latest 13F portfolio value

$4.89B

Market value reported in the latest parsed Form 13F portfolio.

Forms 3/4/5 position value

$173.77M

Estimated from parsed Forms 3/4/5 when the filing discloses enough data.

Leading 13F symbols

ACLX, RVMD, NUVL, PCVX

Largest visible symbols from the latest parsed Form 13F information table.

Top issuer positions

Top parsed positions across ownership filing types.

OLMA

13F holdings

Top symbols from the latest parsed Form 13F information table.

ACLX RVMD NUVL PCVX EWTX GMAB INSM TARS
+12 moreBLTE ERAS CNTA OLMA TERN ORKA APGE SYRE CYTK ABVX TNGX MAZE

Schedule 13G holdings

Large-stake holdings reported on parsed Schedule 13G filings.

MRUS ACLX ERAS EWTX MAZE AGIO
+14 moreJANX COGT CDTX URGN EYPT IRON LENZ VOR OLMA LXEO ACHV YMAB KURA PLRX
How to read these values
  • Filing families stay separate: 13F portfolio value, 13D/G large stakes, and Forms 3/4/5 owner positions should not be blended into one total.
  • Use the linked research paths to verify each signal against the original SEC filing.
Filer identity 1 fact
Business address
520 Fifth Avenue, 23 Rd Floor, New York, NY, 10036
SEC record 2 facts
State of incorporation
DE
Fiscal year-end
31 December

Filer intelligence

What SEC filings say about Paradigm Biocapital Advisors LP

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $4.89B across 35 reported holdings for Q1 2026.
  • Largest parsed 13F holding: ACLX at $662.97M.
  • 5 recent 13D/G stake rows found; top row is ASMB at 5.4% ownership.
  • Forms 3/4/5 show insider context for OLMA worth $173.77M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 35 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2026 - 15 May 2026

Top 5 concentration

48%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$2.37B

Compared with $4.89B total 13F value.

Top 5 net change

+$80.56M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: INSM · Largest trim: CDTX

ACLX RVMD NUVL PCVX EWTX Other holdings

ACLX

13.5%

Arcellx Inc

$662.97M

RVMD

13.2%

Revolution Medicines Inc

$647.27M

NUVL

11.1%

Nuvalent Inc

$545.49M

PCVX

5.7%

Vaxcyte Inc

$278.52M

EWTX

4.7%

Edgewise Therapeutics Inc

$232M

13D/G large-stake context

ASMB

04 May 2026 · Common Stock, $0.001 par value per share

5.4%
Issuer page 13D/G history

ACHV

17 Apr 2026 · Common Stock, $0.001 par value per share

9.2%
Issuer page 13D/G history

LXEO

31 Mar 2026 · Common Stock, $0.0001 par value per share

8.3%
Issuer page 13D/G history

EYPT

31 Mar 2026 · Common Stock, $0.001 par value per share

3.8%
Issuer page 13D/G history

Forms 3/4/5 insider context

OLMA

01 Aug 2024 · 10% owner

$173.77M
Issuer page Owner page

Latest update

What changed recently for Paradigm Biocapital Advisors LP

New filing available

Latest 13F period: Q1 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

15 May 2026

Page type

Filer profile

Latest period

Q1 2026

Institutional portfolio context was refreshed from a 13F filing filed on 15 May 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

Paradigm Biocapital Advisors LP has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q1 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001855655 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
49
First seen
14 Feb 2022
Latest filing
15 May 2026
Entity
Company

Observed form types

13F-HR SCHEDULE 13G SCHEDULE 13G/A

Primary evidence

Open SEC filing index Paradigm Biocapital Advisors LP SEC filings Paradigm Biocapital Advisors LP 13F portfolio Paradigm Biocapital Advisors LP 13D/G history Paradigm Biocapital Advisors LP owner filings

Latest Filings

Showing the latest 12 of 49 SEC filings for Paradigm Biocapital Advisors LP.

Open full filing history
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
15 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
15 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
15 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
15 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
15 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
11 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
24 Apr 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
01 Apr 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
24 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .